AstraZeneca & Daiichi Sankyo’s Enhertu® Receives Time-Limited Reimbursement Recommendation from Canada’s Drug Agency

On 23 May 2025, AstraZeneca and Daiichi Sankyo announced that Canada’s Drug Agency has recommended a Time-Limited Reimbursement for Enhertu® (trastuzumab deruxtecan).  According to AstraZeneca, the recommendation recognises and responds to the unmet need for treatment of adult patients with unresectable, locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen.  This decision marks the first Time-Limited Reimbursement to be awarded to a product used in the treatment of gastric cancer in Canada.